{"name":"Fondazione EMN Italy Onlus","slug":"fondazione-emn-italy-onlus","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Bortezomib, Melphalan, Prednisone","genericName":"Bortezomib, Melphalan, Prednisone","slug":"bortezomib-melphalan-prednisone","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Bortezomib, Melphalan, Prednisone, Thalidomide","genericName":"Bortezomib, Melphalan, Prednisone, Thalidomide","slug":"bortezomib-melphalan-prednisone-thalidomide","indication":"Multiple myeloma (newly diagnosed or relapsed/refractory)","status":"phase_3"},{"name":"Cyclophosphamide, Prednisone, Lenalidomide","genericName":"Cyclophosphamide, Prednisone, Lenalidomide","slug":"cyclophosphamide-prednisone-lenalidomide","indication":"Multiple myeloma (likely indication based on typical use of this triplet)","status":"phase_3"},{"name":"Melphalan, Prednisone, Lenalidomide","genericName":"Melphalan, Prednisone, Lenalidomide","slug":"melphalan-prednisone-lenalidomide","indication":"Multiple myeloma","status":"phase_3"}]}],"pipeline":[{"name":"Bortezomib, Melphalan, Prednisone","genericName":"Bortezomib, Melphalan, Prednisone","slug":"bortezomib-melphalan-prednisone","phase":"phase_3","mechanism":"This combination regimen kills multiple myeloma cells by inhibiting the proteasome (bortezomib), damaging DNA (melphalan), and suppressing immune responses (prednisone).","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)"],"catalyst":""},{"name":"Bortezomib, Melphalan, Prednisone, Thalidomide","genericName":"Bortezomib, Melphalan, Prednisone, Thalidomide","slug":"bortezomib-melphalan-prednisone-thalidomide","phase":"phase_3","mechanism":"This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation.","indications":["Multiple myeloma (newly diagnosed or relapsed/refractory)"],"catalyst":""},{"name":"Cyclophosphamide, Prednisone, Lenalidomide","genericName":"Cyclophosphamide, Prednisone, Lenalidomide","slug":"cyclophosphamide-prednisone-lenalidomide","phase":"phase_3","mechanism":"This combination uses cyclophosphamide and prednisone as immunosuppressive/chemotherapy agents alongside lenalidomide, an immunomodulatory drug that enhances T-cell proliferation and has anti-angiogenic properties.","indications":["Multiple myeloma (likely indication based on typical use of this triplet)"],"catalyst":""},{"name":"Melphalan, Prednisone, Lenalidomide","genericName":"Melphalan, Prednisone, Lenalidomide","slug":"melphalan-prednisone-lenalidomide","phase":"phase_3","mechanism":"Melphalan is an alkylating agent that interferes with DNA replication, Prednisone is a corticosteroid that suppresses the immune system, Lenalidomide is an immunomodulatory drug that affects cell growth and survival.","indications":["Multiple myeloma","Hodgkin lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}